Skip to main content
. Author manuscript; available in PMC: 2016 Jun 20.
Published in final edited form as: Osteoporos Int. 2015 Jun 20;26(11):2677–2684. doi: 10.1007/s00198-015-3173-3

Figure 1.

Figure 1

Hazard ratio (HR) between treatments (teriparatide versus placebo) for morphometric vertebral fractures according to baseline 10-year probability of a major osteoporotic fracture calculated with inclusion of BMD.